<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Case Rep Infect Dis</journal-id><journal-id journal-id-type="iso-abbrev">Case Rep Infect Dis</journal-id><journal-id journal-id-type="publisher-id">CRIID</journal-id><journal-title-group><journal-title>Case Reports in Infectious Diseases</journal-title></journal-title-group><issn pub-type="ppub">2090-6625</issn><issn pub-type="epub">2090-6633</issn><publisher><publisher-name>Hindawi</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6973187</article-id><article-id pub-id-type="pmid">31970003</article-id><article-id pub-id-type="doi">10.1155/2020/5981289</article-id><article-categories><subj-group subj-group-type="heading"><subject>Case Report</subject></subj-group></article-categories><title-group><article-title>Successful Treatment of Adenovirus Infection with Brincidofovir in an Immunocompromised Patient after Hematological Stem Cell Transplantation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Van Genechten</surname><given-names>T.</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4502-1169</contrib-id><name><surname>van Heerden</surname><given-names>J.</given-names></name><email>jaques.vanheerden@uza.be</email><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Bauters</surname><given-names>T.</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="I3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Dhooge</surname><given-names>C.</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="I1">
<sup>1</sup>Pediatric Haematology Oncology and Stem Cell Transplantation, Ghent University Hospital, Ghent, Belgium</aff><aff id="I2">
<sup>2</sup>Pediatric Haematology and Oncology Department, Antwerp University Hospital, Antwerp, Belgium</aff><aff id="I3">
<sup>3</sup>Pharmacy Department, Ghent University Hospital, Ghent, Belgium</aff><author-notes><fn fn-type="other"><p>Academic Editor: Paola Di Carlo</p></fn></author-notes><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>7</day><month>1</month><year>2020</year></pub-date><volume>2020</volume><elocation-id>5981289</elocation-id><history><date date-type="received"><day>28</day><month>8</month><year>2019</year></date><date date-type="accepted"><day>12</day><month>12</month><year>2019</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2020 T. Van Genechten et al.</copyright-statement><copyright-year>2020</copyright-year><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>Immunocompromised patients, including hematopoietic stem cell transplantation (HSCT), HIV, and malnourished patients, are at increased risk for viral infections with high incidences of morbidity and mortality. In HSCT patients, the infection risk is increased until immune reconstitution is re-established. Therapy with standard of care antiviral drugs, for example Cidofovir, is expensive, requires prolonged administration, and has unfavorable toxicity profiles. Our case describes the successful use of Brincidofovir (CMX001), a lipid-conjugate of the nucleotide analog Cidofovir, in a 9-year-old post-HSCT girl with disseminated adenovirus infection. The increased efficacy of Brincidofovir (BCV) against multiple viral infections, limited toxicity, and oral-administered schedule opens options in different resource settings.</p></abstract></article-meta></front><body><sec id="sec1"><title>1. Case Report</title><p>A 9-year-old girl diagnosed with transfusion-dependent refractory cytopenia of childhood (RCC) was treated with a T-cell-depleted haploidentical transplantation from her mother, followed by a second T-cell-depleted haploidentical transplantation from her father due to graft failure. Post-engraftment, she presented with general malaise, weight loss, and vomiting. Concomitant Epstein&#x02013;Barr viral (EBV) reactivation, Herpes simplex (HSV) infection, and Human adenovirus (HAdV) were confirmed by plasma polymerase chain reaction (PCR). EBV was successfully treated with rituximab and HSV with acyclovir. However, as the HAdV viral load (VL) increased to 132&#x02009;&#x000d7;&#x02009;10<sup>6</sup> copies/ml, treatment with 5&#x02009;mg/kg weekly intravenous cidofovir with concomitant hydration only obtained a moderate decrease in the viral load (<xref ref-type="fig" rid="fig1">Figure 1</xref>). The patient rapidly developed renal toxicity. After a minimum of 48-hour dose-to-dose washout interval, after administration of the last dose of intravenous Cidofovir, the first dose of BCV suspension was started. BCV was administered at an oral dose of 2&#x02009;mg/kg, twice weekly. This successfully suppressed the VL with significant clinical improvement. Cholestasis developed one week after the start of BCV treatment. As there were no other concomitant drugs that could have caused cholestasis, BCV treatment was stopped and Cidofovir was restarted. However, as HAdV reactivated, BCV was restarted after resolution of the cholestasis, clearing the VL in the absence of immune reconstitution.</p></sec><sec id="sec2"><title>2. Discussion</title><p>HAdV is a non-enveloped double-stranded DNA virus with over 80 known virus types, divided into seven species [<xref rid="B1" ref-type="bibr">1</xref>&#x02013;<xref rid="B3" ref-type="bibr">3</xref>]. Maternal antibody protection prevents infections before 6 months of age, whereafter endemicity is established in over 80% of children by the age of 6 years [<xref rid="B4" ref-type="bibr">4</xref>]. The incidence does not vary between different countries, but spread, morbidity, and mortality are increased in regions with limited sanitation such as low- and middle-income countries (LMIC) as transmission occurs via droplet, feco-oral, and direct spread [<xref rid="B5" ref-type="bibr">5</xref>].</p><p>After primary infection the virus remains latent in the lymphoreticular system. In immunocompetent individuals persistent shedding is present, but in immunocompromised individuals, reactivation increases morbidity and mortality rates [<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B4" ref-type="bibr">4</xref>].</p><p>Our patient was both T- and B-cell-depleted due to the double haploidentical HSCT, conditioning regimens with antithymocyte globulin and rituximab treatment. Without HAdV specific CD4+ helper, CD8+ cytotoxic T cells and inadequate clearance, the HAdV caused a symptomatic viraemia [<xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B7" ref-type="bibr">7</xref>]. Other immunocompromised patients (e.g., severe combined immunodeficiency or HIV-patients) might as well benefit from easily accessible drugs with a reasonably safe toxic profile [<xref rid="B8" ref-type="bibr">8</xref>].</p><p>Treatment of HAdV infection in immunocompromised patients is ineffective without immune reconstitution [<xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B7" ref-type="bibr">7</xref>]. Cidofovir requires regular intravenous dosing but only achieves low in vivo activity due to low intracellular levels (see <xref ref-type="fig" rid="fig2">Figure 2(a)</xref>), and therefore poor results [<xref rid="B9" ref-type="bibr">9</xref>]. This might obtain viral control but hardly ever viral clearance. Cidofovir is most effective as prophylaxis with increasing titres on stool samples, plasma PCR's or early onset disease [<xref rid="B10" ref-type="bibr">10</xref>]. The side effect profile includes nausea, vomiting, myelosuppression and severe renal tubulopathies [<xref rid="B8" ref-type="bibr">8</xref>]. During treatment the direct and indirect costs increase due to in-hospital toxicity monitoring and mandatory adequate hydration.</p><p>Brincidofovir, the lipid-conjugate of the nucleotide analog Cidofovir, can achieve over 100-fold higher intracellular levels compared with Cidofovir (see <xref ref-type="fig" rid="fig2">Figure 2(b)</xref>). The low plasma levels promote less toxicity, and nephrotoxicity is avoided as there is no binding to anion transporters in the kidney [<xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B11" ref-type="bibr">11</xref>]. BCV has a twice weekly oral dosing, low toxicity, and broad spectrum antiviral activity, including CMV, EBV, acyclovir-resistant HSV, and BK-virus, even without immune reconstitution [<xref rid="B11" ref-type="bibr">11</xref>].</p><p>Adoptive immunotherapy by means of donor leukocyte infusion has been used, curing HAdV infection, but carries the risk of developing graft versus host reactions. Therapies such as modified HAdV-specific T-cells are expensive and time consuming with complex administration procedures [<xref rid="B12" ref-type="bibr">12</xref>].</p><p>In LMIC, high viral infection susceptibilities in patients with HIV, malnutrition, chronic diseases, malignancies, as well as increasing organ transplantation, family-related donor and haploidentical HSCT, resource sensitive alternatives are essential. Brincidofovir could fill in this gap, provided its availability is guaranteed.</p></sec><sec id="sec3"><title>3. Conclusion</title><p>BCV can successfully treat HAdV infection in post-transplant immunocompromised children. Although direct drug costs have not been determined, indirect cost savings on hospitalization, staffing, screening, and procedures in multiple disease profiles makes BCV a promising drug for resource-limited settings.</p></sec></body><back><sec><title>Disclosure</title><p>Copyright of pharmacokinetic images is with the pharmaceutical company, Chimerix.</p></sec><sec sec-type="COI-statement"><title>Conflicts of Interest</title><p>The authors have no conflicts of interest to declare.</p></sec><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feuchtinger</surname><given-names>T.</given-names></name><name><surname>Lang</surname><given-names>P.</given-names></name><name><surname>Handgretinger</surname><given-names>R.</given-names></name></person-group><article-title>Adenovirus infection after allogeneic stem cell transplantation</article-title><source><italic toggle="yes">Leukemia &#x00026; Lymphoma</italic></source><year>2007</year><volume>48</volume><issue>2</issue><fpage>244</fpage><lpage>255</lpage><pub-id pub-id-type="doi">10.1080/10428190600881157</pub-id><pub-id pub-id-type="other">2-s2.0-34247842876</pub-id><pub-id pub-id-type="pmid">17325884</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walls</surname><given-names>T.</given-names></name><name><surname>Shankar</surname><given-names>A.</given-names></name><name><surname>Shingadia</surname><given-names>D.</given-names></name></person-group><article-title>Adenovirus: an increasingly important pathogen in paediatric bone marrow transplant patients</article-title><source><italic toggle="yes">The Lancet Infectious Diseases</italic></source><year>2003</year><volume>3</volume><issue>2</issue><fpage>79</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1016/s1473-3099(03)00515-2</pub-id><pub-id pub-id-type="other">2-s2.0-0037310655</pub-id><pub-id pub-id-type="pmid">12560192</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heemskerk</surname><given-names>B.</given-names></name><name><surname>Lankester</surname><given-names>A. C.</given-names></name><name><surname>van Vreeswijk</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Immune reconstitution and clearance of human adenovirus viremia in pediatric stem-cell recipients</article-title><source><italic toggle="yes">The Journal of Infectious Diseases</italic></source><year>2005</year><volume>191</volume><issue>4</issue><fpage>520</fpage><lpage>530</lpage><pub-id pub-id-type="doi">10.1086/427513</pub-id><pub-id pub-id-type="other">2-s2.0-13444256480</pub-id><pub-id pub-id-type="pmid">15655775</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>WY Ip</surname><given-names>W.</given-names></name><name><surname>Qasim</surname><given-names>W.</given-names></name></person-group><article-title>Management of adenovirus in children after allogeneic hematopoietic stem cell transplantation</article-title><source><italic toggle="yes">Advances in Hematology</italic></source><year>2013</year><volume>2013</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1155/2013/176418</pub-id><pub-id pub-id-type="other">2-s2.0-84888591443</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moyo</surname><given-names>S. J.</given-names></name><name><surname>Hanevik</surname><given-names>K.</given-names></name><name><surname>Blomberg</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Prevalence and molecular characterisation of human adenovirus in diarrhoeic children in Tanzania; a case control study</article-title><source><italic toggle="yes">BMC Infectious Diseases</italic></source><year>2014</year><volume>14</volume><issue>1</issue><pub-id pub-id-type="doi">10.1186/s12879-014-0666-1</pub-id><pub-id pub-id-type="other">2-s2.0-84924032679</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feuchtinger</surname><given-names>T.</given-names></name><name><surname>Richard</surname><given-names>C.</given-names></name><name><surname>Pfeiffer</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Adenoviral infections after transplantation of positive selected stem cells from haploidentical donors in children: an update</article-title><source><italic toggle="yes">Klinische P&#x000e4;diatrie</italic></source><year>2005</year><volume>217</volume><issue>6</issue><fpage>339</fpage><lpage>344</lpage><pub-id pub-id-type="doi">10.1055/s-2005-872530</pub-id><pub-id pub-id-type="other">2-s2.0-28544440253</pub-id><pub-id pub-id-type="pmid">16307420</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taniguchi</surname><given-names>K.</given-names></name><name><surname>Yoshihara</surname><given-names>S.</given-names></name><name><surname>Tamaki</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Incidence and treatment strategy for disseminated adenovirus disease after haploidentical stem cell transplantation</article-title><source><italic toggle="yes">Annals of Hematology</italic></source><year>2012</year><volume>91</volume><issue>8</issue><fpage>1305</fpage><lpage>1312</lpage><pub-id pub-id-type="doi">10.1007/s00277-012-1440-3</pub-id><pub-id pub-id-type="other">2-s2.0-84865023157</pub-id><pub-id pub-id-type="pmid">22476883</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wold</surname><given-names>W. S.</given-names></name><name><surname>Toth</surname><given-names>K.</given-names></name></person-group><article-title>New drug on the horizon for treating adenovirus</article-title><source><italic toggle="yes">Expert Opinion on Pharmacotherapy</italic></source><year>2015</year><volume>16</volume><issue>14</issue><fpage>2095</fpage><lpage>2099</lpage><pub-id pub-id-type="doi">10.1517/14656566.2015.1083975</pub-id><pub-id pub-id-type="other">2-s2.0-84941422055</pub-id><pub-id pub-id-type="pmid">26330121</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Symeonidis</surname><given-names>N.</given-names></name><name><surname>Jakubowski</surname><given-names>A.</given-names></name><name><surname>Pierre-Louis</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Invasive adenoviral infections in T-cell-depleted allogeneic hematopoietic stem cell transplantation: high mortality in the era of cidofovir</article-title><source><italic toggle="yes">Transplant Infectious Disease</italic></source><year>2007</year><volume>9</volume><issue>2</issue><fpage>108</fpage><lpage>113</lpage><pub-id pub-id-type="doi">10.1111/j.1399-3062.2006.00184.x</pub-id><pub-id pub-id-type="other">2-s2.0-34247596927</pub-id><pub-id pub-id-type="pmid">17461995</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lindemans</surname><given-names>C. A.</given-names></name><name><surname>Leen</surname><given-names>A. M.</given-names></name><name><surname>Boelens</surname><given-names>J. J.</given-names></name></person-group><article-title>How I treat adenovirus in hematopoietic stem cell transplant recipients</article-title><source><italic toggle="yes">Blood</italic></source><year>2010</year><volume>116</volume><issue>25</issue><fpage>5476</fpage><lpage>5485</lpage><pub-id pub-id-type="doi">10.1182/blood-2010-04-259291</pub-id><pub-id pub-id-type="other">2-s2.0-78650489175</pub-id><pub-id pub-id-type="pmid">20837781</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hiwarkar</surname><given-names>P.</given-names></name><name><surname>Amrolia</surname><given-names>P.</given-names></name><name><surname>Sivaprakasam</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Brincidofovir is highly efficacious in controlling adenoviremia in pediatric recipients of hematopoietic cell transplant</article-title><source><italic toggle="yes">Blood</italic></source><year>2017</year><volume>129</volume><issue>14</issue><fpage>2033</fpage><lpage>2037</lpage><pub-id pub-id-type="doi">10.1182/blood-2016-11-749721</pub-id><pub-id pub-id-type="other">2-s2.0-85021713146</pub-id><pub-id pub-id-type="pmid">28153824</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reis</surname><given-names>M.</given-names></name><name><surname>Ogonek</surname><given-names>J.</given-names></name><name><surname>Qesari</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Recent developments in cellular immunotherapy for HSCT-associated complications</article-title><source><italic toggle="yes">Frontiers in Immunology</italic></source><year>2016</year><volume>7</volume><fpage>p. 500</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2016.00500</pub-id><pub-id pub-id-type="other">2-s2.0-85006173390</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="fig1" orientation="portrait" position="float"><label>Figure 1</label><caption><p>The viral load response during the treatment with Cidofovir and Brincidofovir.</p></caption><graphic xlink:href="CRIID2020-5981289.001"/></fig><fig id="fig2" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Pharmacokinetics and drug composition of Cidofovir and Brincidofovir. (a) The activated antiviral, cidofovir diphosphate, leads to chain termination as it is incorporated into the viral DNA. (b) In Brincidofovir, the lipid conjugated form of Cidofovir, intracellular uptake is increased leading to a more than 100-fold increase in intracellular concentration of active cidofovir.</p></caption><graphic xlink:href="CRIID2020-5981289.002"/></fig></floats-group></article>